Project Grant R43HL137416

This Project Grant award of $1,290,338 from the National Heart Lung and Blood Institute (CFDA 93.837 - Cardiovascular Diseases Research) supports research conducted by Jaan Biotherapeutics, Inc. to develop a gene therapy treatment for heart muscle regeneration after myocardial infarction. The research aims to inhibit four specific microRNAs that regulate cardiomyocyte dedifferentiation, proliferation, and redifferentiation, with the goal of stimulating endogenous heart muscle regeneration and...

The National Heart, Lung, and Blood Institute awarded a $989,908 Project Grant under the Cardiovascular Diseases Research program (CFDA 93.837) to the University of Nevada, Las Vegas (UNLV) to investigate the use of Wnt11-treated mesenchymal stem cells (MSCs) for improving cardiac repair after myocardial infarction. The 4-year project aims to examine if Wnt11 treatment can enhance MSC retention, survival, and reparative effects in vitro and in a mouse model of reperfused myocardial infarction....

The National Heart, Lung, and Blood Institute (NHLBI), under the Cardiovascular Diseases Research program (CFDA 93.837), awarded a $402,911 Project Grant to The Trustees of Columbia University in the City of New York to develop a pericardial mRNA therapy for the treatment of myocardial infarction (heart attack). The research aims to create a new anti-inflammatory drug based on previous studies of stem cell derivatives for heart repair, which will be administered via minimally invasive...

The National Heart, Lung, and Blood Institute (NHLBI) awarded a $243,000 Project Grant under the Cardiovascular Diseases Research program (CFDA 93.837) to the University of Cincinnati's Sponsored Research Services Division. The grant will fund a 2-year project to engineer advanced RNA biodevices that leverage CRISPR and ADAR gene-editing technologies. The goal is to improve the efficiency and specificity of converting resident cardiac fibroblasts into functional cardiomyocytes, in order to boost...

This federal Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI), under the Cardiovascular Diseases Research program (CFDA 93.837), provides $833,594 to investigate the pro-regenerative potential of the Pontin gene in the heart. The research aims to decipher the gene regulatory networks controlling cardiomyocyte (heart muscle cell) proliferation, with the goal of identifying druggable pathways to stimulate heart regeneration as a remedy for myocardial infarction....

This Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI), part of the Cardiovascular Diseases Research federal grant program (CFDA 93.837), provides $694,252.00 to Cedars-Sinai Medical Center in California to investigate the mechanisms of cardioprotective Y RNA signaling in macrophages. The goal is to better understand how a small non-coding RNA called YREX3 can enhance the ability of macrophages to clear dead cells and promote cardiac tissue healing after a myocardial...

This Project Grant award from the National Heart, Lung, and Blood Institute (CFDA 93.837 Cardiovascular Diseases Research) provides $496,367.00 to Duke University to support research on novel approaches for cardiac reprogramming. Specifically, the project aims to improve the efficacy of in-situ reprogramming of scar fibroblasts into cardiomyocytes through three key objectives: Investigating the mechanism by which a repressor complex inhibits cardiomyocyte gene expression, including testing...

This Project Grant award from the National Heart, Lung, and Blood Institute (CFDA 93.837 Cardiovascular Diseases Research) provides $729,703 to The Trustees of Columbia University in the City of New York to develop a technology called "NanoVials" to sort and enrich mesenchymal stem cells (MSCs) based on their extracellular vesicle (EV) secretion levels. The goal is to optimize stem cell therapies for ischemic diseases like myocardial infarction by identifying and utilizing MSCs with...

The National Heart, Lung, and Blood Institute (NHLBI) awarded a $361,083 Project Grant under the Cardiovascular Diseases Research program (CFDA 93.837) to the Children's Hospital Medical Center in Cincinnati, OH. The grant supports research on how acetylation regulates the subcellular localization of the transcription factor YAP and its role in cardiac regeneration. The 5-year project aims to investigate how metabolic stresses affect YAP acetylation through the NAD+/SIRT1/2 axis, and whether...

This Project Grant award from the National Heart, Lung, and Blood Institute (CFDA 93.837 - Cardiovascular Diseases Research) provides $388,036 to Laborecom Therapeutics Inc. to develop a novel therapeutic peptide to reduce myocardial reperfusion injury. The goal is to optimize the peptide's stability, permeability, and activity, and then evaluate its ability to improve heart function and limit infarct size in a mouse model of myocardial infarction. Successful completion of this Phase I SBIR...